Key result
Genetic testing for lipid disorders increases diagnostic accuracy and risk stratification, and should be selectively used according to dyslipidemia type when benefits outweigh costs.
Why the study?
Advances in genetics created a gap between theoretical knowledge and its applicability in clinical practice, making it important to define the clinical justification of genetic testing in dyslipidemia patients.
What is the clinical impact and justification of genetic testing in patients with dyslipidemia?
What is the clinical impact and justification of genetic testing in patients with dyslipidemia?
Genetic testing for lipid disorders is currently underutilized but can improve diagnostic accuracy, risk stratification, and access to specialty therapies when used selectively.
Should not yet change practice for dyslipidemia genetic testing; leaves open need for prospective validation of selective use.
PURPOSE OF REVIEW: Genetic testing is increasingly becoming a common consideration in the clinical approach of dyslipidemia patients. Advances in research in last decade and increased recognition of genetics in biological pathways modulating blood lipid levels created a gap between theoretical knowledge and its applicability in clinical practice. Therefore, it is very important to define the clinical justification of genetic testing in dyslipidemia patients. RECENT FINDINGS: Clinical indications for genetic testing for most dyslipidemias are not precisely defined and there are no clearly established guideline recommendations. In patients with severe low-density lipoprotein cholesterol (LDL-C) levels, the genetic analysis can be used to guide diagnostic and therapeutic approach, while in severe hypertriglyceridemia (HTG), clinicians can rely on triglyceride level rather than a genotype along the treatment pathway. Genetic testing increases diagnostic accuracy and risk stratification, access and adherence to specialty therapies, and cost-effectiveness of cascade testing. A shared decision-making model between the provider and the patient is essential as patient values, preferences and clinical characteristics play a very strong role. SUMMARY: Genetic testing for lipid disorders is currently underutilized in clinical practice. However, it should be selectively used, according to the type of dyslipidemia and when the benefits overcome costs.
No takes yet. Share an insight, caveat, or question.
Muzurović et al. (2024) conducted a review in Lipid disorders (dyslipidemia). Genetic testing was evaluated. Genetic testing for lipid disorders increases diagnostic accuracy and risk stratification, and should be selectively used according to dyslipidemia type when benefits outweigh costs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: